Review Article | Published:

Evolving concepts of rheumatoid arthritis

Nature volume 423, pages 356361 (15 May 2003) | Download Citation

Subjects

Abstract

Rheumatoid arthritis is the most common inflammatory arthritis and is a major cause of disability. It existed in early Native American populations several thousand years ago but might not have appeared in Europe until the 17th century. Early theories on the pathogenesis of rheumatoid arthritis focused on autoantibodies and immune complexes. T-cell-mediated antigen-specific responses, T-cell-independent cytokine networks, and aggressive tumour-like behaviour of rheumatoid synovium have also been implicated. More recently, the contribution of autoantibodies has returned to the forefront. Based on the pathogenic mechanisms, specific therapeutic interventions can be designed to suppress synovial inflammation and joint destruction in rheumatoid arthritis.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , & An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J. Exp. Med. 105, 425–435 (1957).

  2. 2.

    The immunopathology of joint inflammation in rheumatoid arthritis. Adv. Immunol. 16, 265–336 (1973).

  3. 3.

    et al. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 46, 934–945 (2002).

  4. 4.

    & Activation of the complement and properdin systems in rheumatoid arthritis. Ann. NY Acad. Sci. 256, 96–104 (1975).

  5. 5.

    Mixed lymphocyte cultures in rheumatoid arthritis. J. Clin. Invest. 57, 1148–1157 (1976).

  6. 6.

    et al. HLA genes associated with rheumatoid arthritis: identification of susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum. 32, 15–21 (1989).

  7. 7.

    , , & The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann. Intern. Med. 117, 801–803 (1992).

  8. 8.

    et al. Structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368, 215–221 (1994).

  9. 9.

    et al. Naturally processed peptides from rheumatoid arthritis and non-associated HLA-DR alleles. J. Immunol. 155, 5655–5662 (1995).

  10. 10.

    The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum. 40, 598–609 (1997).

  11. 11.

    et al. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum. 40, 1115–1125 (1997).

  12. 12.

    et al. Isolation and characteristics of autoreactive T cells specific to aggrecan G1 domain from rheumatoid arthritis patients. Cell Res. 10, 39–49 (2000).

  13. 13.

    et al. Antibodies to 65Kd heat-shock protein were elevated in rheumatoid arthritis. Clin. Rheumatol. 13, 261–264 (1994).

  14. 14.

    , , , & Collagen antibodies in rheumatoid arthritis. Significance of antibodies to denatured collagen and their association with HLA-DR4. Arthritis Rheum. 29, 174–184 (1986).

  15. 15.

    , , , & Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283, 666–668 (1980).

  16. 16.

    , & Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 144, 3347–3353 (1990).

  17. 17.

    et al. Poor expression of T cell-derived cytokines and activation and proliferation markers in early rheumatoid synovial tissue. Clin. Immunol. Immunopathol. 88, 84–90 (1998).

  18. 18.

    , , & Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl Acad. Sci. USA 91, 2762–2766 (1994).

  19. 19.

    et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. 108, 1781–1788 (2001).

  20. 20.

    & How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum. 33, 768–773 (1990).

  21. 21.

    & Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163–196 (2001).

  22. 22.

    et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J. Clin. Invest. 104, 1393–1401 (1999).

  23. 23.

    et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101, 746–754 (1998).

  24. 24.

    , , & Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J. Immunol. 161, 409–414 (1998).

  25. 25.

    et al. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: involvement of membrane-associated cytokines. Arthritis Rheum. 41, 1748–1759 (1998).

  26. 26.

    et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343, 1594–1602 (2000).

  27. 27.

    et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110, 1419–1427 (2002).

  28. 28.

    et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance. J. Immunol. 170, 2655–2662 (2003).

  29. 29.

    et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment. Arthritis Rheum. 46, 1744–1753 (2002).

  30. 30.

    et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304–309 (1999).

  31. 31.

    et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 159, 1689–1699 (2001).

  32. 32.

    , , & AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28, 197–208 (1998).

  33. 33.

    et al. NF-κB regulation by IκB kinase-2 in rheumatoid arthritis synoviocytes. J. Immunol. 166, 2705–2711 (2001).

  34. 34.

    et al. Inhibitor of nuclear factor κB kinase β is a key regulator of synovial inflammation. Arthritis Rheum. 44, 1897–1907 (2001).

  35. 35.

    et al. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc. Natl Acad. Sci. USA 95, 13859–13864 (1998).

  36. 36.

    et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 43, 2501–2512 (2000).

  37. 37.

    et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 279, 1453–1461 (1996).

  38. 38.

    et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 108, 73–81 (2001).

  39. 39.

    , , , & Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum. 46, 818–823 (2002).

  40. 40.

    et al. Synovial fibroblast-like cells strongly express jun-B and C-fos proto-oncogenes in rheumatoid-and osteoarthritis. Scand. J. Rheumatol. Suppl. 101, 121–125 (1995).

  41. 41.

    , , & Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J. Clin. Invest. 99, 1210–1216 (1997).

  42. 42.

    et al. Monoclonal expansion of synoviocytes in rheumatoid arthritis. Arthritis Rheum. 41, 1979–1986 (1998).

  43. 43.

    et al. Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion. Arthritis Rheum. 44, 676–681 (2001).

  44. 44.

    , , , & Blockade of Wnt-5A/Frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum. 44, 772–781 (2001).

  45. 45.

    , , & Focally regulated endothelial proliferation and cell death in human synovium. Am. J. Pathol. 152, 691–702 (1998).

  46. 46.

    et al. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc. Natl Acad. Sci. USA 94, 10895–10900 (1997).

  47. 47.

    et al. Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue. Clin. Exp. Immunol. 111, 353–358 (1998).

  48. 48.

    et al. Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium. Rheumatology 39, 262–266 (2000).

  49. 49.

    et al. Microsatellite instability and suppressed DNA repair enzyme expression in rheumatoid arthritis. J. Immunol. 170, 2214–2220 (2003).

  50. 50.

    et al. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc. Natl Acad. Sci. USA 99, 10025–10030 (2002).

  51. 51.

    et al. Organ-specific disease provoked by systemic autoimmunity. Cell 87, 811–822 (1996).

  52. 52.

    et al. Arthritis critically dependent on innate immune system players. Immunity 16, 157–168 (2002).

  53. 53.

    et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum. 48, 944–954 (2003).

  54. 54.

    & Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. 4, S1–S5 (2002).

  55. 55.

    et al. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum. 46, 1185–1195 (2002).

  56. 56.

    & B cells in rheumatoid arthritis. Arthritis Res. 2, 126–131 (2000).

  57. 57.

    et al. Clonally-related immunoglobulin VH domains and nonrandom use of DH gene segments in rheumatoid arthritis synovium. Mol. Med. 4, 240–251 (1998).

  58. 58.

    et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297, 1689–1692 (2002).

  59. 59.

    et al. Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 22, 137–147 (1995).

  60. 60.

    et al. Immunostimulatory DNA sequences influence the course of adjuvant arthritis. J. Immunol. 168, 51–56 (2002).

  61. 61.

    et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141–147 (1997).

  62. 62.

    et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105–1110 (1994).

  63. 63.

    , , , & Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244–247 (2001).

  64. 64.

    et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J. Clin. Invest. 105, 1697–1710 (2000).

  65. 65.

    , , , & Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. J. Rheumatol. 26, 2089–2093 (1999).

  66. 66.

    et al. Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera. J. Rheumatol. 29, 1609–1614 (2002).

  67. 67.

    et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 46, 2029–2033 (2002).

  68. 68.

    et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nature Immunol. 2, 632–637 (2001).

  69. 69.

    et al. Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum. 46, 3065–3075 (2002).

  70. 70.

    & How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end. Arthritis Rheum. 46, 298–308 (2002).

  71. 71.

    et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum. 43, 593–598 (2000).

  72. 72.

    , , , & HLA-DRB1 molecules and antigenic experience shape the repertoire of CD4 T cells. Hum. Immunol. 44, 203–209 (1995).

  73. 73.

    et al. T cell selection and differential activation on structurally related HLA-DR4 ligands. J. Immunol. 167, 3250–3256 (2001).

  74. 74.

    , & HLA association with autoimmune disease: a failure to protect? Rheumatology 39, 1060–1066 (2000).

  75. 75.

    , , , & Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110. Proc. Natl Acad. Sci. USA 86, 5104–5108 (1989).

  76. 76.

    , , & Paleopathology in osseous remains from the 16th century. A survey of rheumatic diseases. J. Rheumatol. 25, 776–782 (1998).

  77. 77.

    , & Symmetrical erosive peripheral polyarthritis in the Late Archaic Period of Alabama. Science 241, 1498–1501 (1988).

Download references

Acknowledgements

Supported by grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The author also thanks N. J. Zvaifler for helpful discussions on this topic as well as two decades of instruction, collaboration and friendship.

Author information

Corresponding author

Correspondence to Gary S. Firestein.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nature01661

Authors

  1. Search for Gary S. Firestein in:

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing